Developing novel drugs for the treatment of cancer. First lead compound advancing up to clinics, has proven in vitro and in vivo efficacy and a good pharmacology profile.

First indication sought is the treatment of malignant mesothelioma: a rare, aggresive and incurable cancer with limited therapeutic options.

We are looking a round of 6.3 milion euros to complete manufacture and perform first in man clinical studies.


I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Deja un comentario

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *